T.Villalobos-PerezA.CogenF.et al (2021)
According to the 2024 American Diabetes Association Standards of Care, GLP-1 receptor agonists have become first line pharmacotherapy for most patients with type 2 diabetes mellitus (T2DM), including those with concomitant atherosclerotic cardiovascular disease (ASCVD), indicators of high ASCVD risk, or chronic kidney disease
Qi X, Wang J
Similar results have been obtained with drugs targeting NPY receptors
PubMed Rhim HC, et al
l, sugar, sugar, caramellised syrup, emulsifiers mono- and diglycerides of fatty acids, salt, flavours), peanuts (8.8%), sorbitol syrup (4.6%), tricalcium phosphate, flavours, L-carnitine tartrate (0.3%), vitamins (vitamin C (ascorbic acid), niacin (nicotine acetamide), tocopheryl